Literature DB >> 27508019

miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.

Suna Zhou1, Wenguang Ye2, Yanjun Zhang1, Dequan Yu1, Qiuju Shao1, Jun Liang1, Mingxin Zhang2.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Chemoresistance occurrence is a major cause of treatment failure in HCC. Currently, extensive research has revealed diverse mechanisms for chemoresistance, but the molecular mechanisms underlying the role of miRNAs in resistance to 5-FU are not confirmed in HCC cells. By quantitative real-time polymerase chain reaction (qRT-PCR) analysis, we found that miR-144 was significantly decreased in HCC cell lines. It has been further demonstrated that miR-144 were significantly down-regulated in Bel-7402/5-FU cells compared with parental Bel-7402 cells by qRT-PCR and western blot. The expression of Nrf2 was reversely correlated to that of miR-144 in HCC cells. Moreover, Enhancement of 5-FU-induced cytotoxicity and apoptosis are resulted from the transfection with miR-144 mimics in Bel-7402/5-FU cells. Mechanically, miR-144 promoted nuclear factor erythroid-2-related factor-2 (Nrf2) mRNA degradation by directly targeting the Nrf2 3'untranslated region (3'UTR). In addition, ectopic expression of miR-144 in Bel-7402/5-FU cells reduced the levels of Nrf2 and inhibited the transcription of Nrf2-dependent HO-1 gene, thus contributing to 5-FU sensibilization. Conversely, re-expression of Nrf2 partly attenuated the chemosensibilization of miR-144. Our study showed that miR-144 serves as a potential chemoresistance-reversal agent in hepatocellular carcinoma cells, which is at least partly due to the down-regulation of Nrf2-dependent antioxidant pathway.

Entities:  

Keywords:  Hepatocellular carcinoma; Nrf2; chemoresistance; miR-144

Year:  2016        PMID: 27508019      PMCID: PMC4969435     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  24 in total

1.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer.

Authors:  Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy.

Authors:  Melanie B Thomas; James P O'Beirne; Junji Furuse; Anthony T C Chan; Ghassan Abou-Alfa; Philip Johnson
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

3.  MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.

Authors:  Liang Shi; Lili Wu; Zhanguo Chen; Jianrong Yang; Xiaofei Chen; Fangyou Yu; Fang Zheng; Xiangyang Lin
Journal:  Cell Physiol Biochem       Date:  2015-04-15

4.  Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1.

Authors:  Xiang Li; Xiaolei Li; Daixiang Liao; Xiaohui Wang; Zhiqiang Wu; Jing Nie; Miaomiao Bai; Xiaobing Fu; Qian Mei; Weidong Han
Journal:  Curr Protein Pept Sci       Date:  2015       Impact factor: 3.272

5.  Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.

Authors:  Jessica A Davila; Zhigang Duan; Katherine A McGlynn; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2012-01       Impact factor: 3.062

6.  MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer.

Authors:  Z Sun; N Zhou; Q Han; L Zhao; C Bai; Y Chen; J Zhou; R C Zhao
Journal:  Clin Transl Oncol       Date:  2015-06-09       Impact factor: 3.405

7.  MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Cristina Caramés; Ion Cristóbal; Víctor Moreno; Laura del Puerto; Irene Moreno; María Rodriguez; Juan P Marín; Andrea V Correa; Roberto Hernández; Víctor Zenzola; Tatiana Hernández; Ana León; José I Martín; Paloma Sánchez-Fayos; Damián García-Olmo; Federico Rojo; Ajay Goel; María J Fernandez-Aceñero; Jesús García-Foncillas
Journal:  Int J Colorectal Dis       Date:  2015-05-08       Impact factor: 2.571

8.  miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.

Authors:  Tao Li; Feng Gao; Xi-Peng Zhang
Journal:  Oncol Rep       Date:  2014-12-04       Impact factor: 3.906

9.  MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis.

Authors:  Xiao-Ying Huang; Jin-Guang Yao; Hong-Dong Huang; Chao Wang; Yun Ma; Qiang Xia; Xi-Dai Long
Journal:  Gastroenterol Res Pract       Date:  2013-09-24       Impact factor: 2.260

10.  miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.

Authors:  Angela M Liu; Zhi Xu; Felix H Shek; Kwong-Fai Wong; Nikki P Lee; Ronnie T Poon; Jinfei Chen; John M Luk
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more
  24 in total

Review 1.  Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.

Authors:  Xingguo Zhu; Aluya R Oseghale; Lopez H Nicole; Biaoru Li; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-23

2.  miR-144 suppresses cell proliferation and invasion in gastric cancer through downregulation of activating enhancer-binding protein 4.

Authors:  Faheim Mushtaq; Jinping Zhang; Jiansheng Li
Journal:  Oncol Lett       Date:  2019-04-04       Impact factor: 2.967

3.  Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation.

Authors:  Jing Liu; Liguo Feng; Haitao Zhang; Jin Zhang; Yanyan Zhang; Shujing Li; Long Qin; Ziyao Yang; Jianxia Xiong
Journal:  Cancer Biol Ther       Date:  2018-03-26       Impact factor: 4.742

Review 4.  Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters.

Authors:  Mehdi Rabiee Valashedi; Chia Bamshad; Nima Najafi-Ghalehlou; Amirsadegh Nikoo; Kazuo Tomita; Yoshikazu Kuwahara; Tomoaki Sato; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar
Journal:  Hum Cell       Date:  2022-04-12       Impact factor: 4.174

Review 5.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

6.  miR-144 inhibits the IGF1R-ERK1/2 signaling pathway via NUDCD1 to suppress the proliferation and metastasis of colorectal cancer cells: a study based on bioinformatics and in vitro and in vivo verification.

Authors:  Bin Han; Ke Xu; Dan Feng; Yang Bai; Yangqi Liu; Yuanyuan Zhang; Liming Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-27       Impact factor: 4.322

Review 7.  The intricacies of NRF2 regulation in cancer.

Authors:  Cody J Schmidlin; Aryatara Shakya; Matthew Dodson; Eli Chapman; Donna D Zhang
Journal:  Semin Cancer Biol       Date:  2021-05-18       Impact factor: 15.707

8.  A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma.

Authors:  Hai-Wei Liang; Zhi-Hua Ye; Shu-Ya Yin; Wei-Jia Mo; Han-Lin Wang; Jin-Che Zhao; Guo-Mei Liang; Zhen-Bo Feng; Gang Chen; Dian-Zhong Luo
Journal:  Onco Targets Ther       Date:  2017-07-11       Impact factor: 4.147

9.  Antihepatocarcinoma Effect of Portulaca oleracea L. in Mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB Pathway.

Authors:  Zheng Guoyin; Peng Hao; Li Min; Gu Wei; Chen Zhe; Ling Changquan
Journal:  Evid Based Complement Alternat Med       Date:  2017-06-04       Impact factor: 2.629

10.  A20 enhances the radiosensitivity of hepatocellular carcinoma cells to 60Co-γ ionizing radiation.

Authors:  Rui Liu; Dongli Zhao; Xiaozhi Zhang; Suxia Han; Yunyi Yang; Jinlu Ma; Du Meng
Journal:  Oncotarget       Date:  2017-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.